Malignant Breast Neoplasm

PTEN loss is associated with loss of sensitivity to the HER2-antibody trastuzumab in breast cancer in smaller trials, a phase III trial (NCCTG N9831) did not show an effect of PTEN on disease-free sur… (full text at CIViC)

PMID 24387334 · Dillon et al., 2014 · Open in CIViC

A large-scale RNAi genetic sereen in HER2 overexpressing breast cancer cell line BT-474 was performed to discover genes whose loss induced trastuzumab resistance. The most prominently enriched gene in… (full text at CIViC)

PMID 17936563 · Berns et al., 2007 · Open in CIViC

In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors had decreased, slightly decreased, or absent PTEN expression (assessed by IHC) treated with ad… (full text at CIViC)

PMID 26920887 · Baselga et al., 2016 · Open in CIViC

Knockdown of PTEN in trastuzumab sensitive HER2 breast cancer BT474 cells induced trastuzumab resistance. PTEN null cells treated with PI3K inhibitor LY294002 also did not show substantial inhibition,… (full text at CIViC)

PMID 15324695 · Nagata et al., 2004 · Open in CIViC

Cells with PTEN deficiency have been shown to exhibit slowed growth in reponse to PI3K-mTOR inhibitors.

PMID 20085938 · Courtney et al., 2010 · Open in CIViC

Cancer-associated mutation of PTPN12 or reduced PTPN12 protein leads to aberrant activity of several tyrosine kinase receptors (MET, PDGFRβ, EGFR, and others). Restoring PTPN12 protein levels restrain… (full text at CIViC)

PMID 29578538 · Nair et al., 2018 · Open in CIViC

A healthy, 36-year-old woman presented with a palpable right breast mass upon biopsy determined to be high-grade, triple negative invasive ductal carcinoma. Her family history was notable for multiple… (full text at CIViC)

PMID 25445424 · Baker et al., 2015 · Open in CIViC

A drug screen of triple-negative breast cancer (TNBC) cell lines found several therapies to be synthetically lethal with RB1 loss of function. Cell lines with endogenous expression of RB1 (BT20, MB453… (full text at CIViC)

PMID 29386107 · Witkiewicz et al., 2018 · Open in CIViC

A drug screen of triple-negative breast cancer (TNBC) cell lines found several therapies to be synthetically lethal with RB1 loss of function. Cell lines with endogenous expression of RB1 (BT20, MB453… (full text at CIViC)

PMID 29386107 · Witkiewicz et al., 2018 · Open in CIViC

Three patients with hormone receptor positive metastastic breast cancer, treated with letrozol/ribociclib or fulvestrant/palbociclib, underwent RB1 gene sequencing before, during and after acquiring r… (full text at CIViC)

PMID 29236940 · Condorelli et al., 2018 · Open in CIViC

The p110alpha-specific PI3K inhibitor BYL719 (Alpelisib) was used on a panel of five PI3K inhibitor sensitive and five resistant breast cancer cell lines. Sensitive cells (IC50<400nM) showed reduced p… (full text at CIViC)

PMID 25002028 · Vora et al., 2014 · Open in CIViC

Vandetanib was tested in 4 murine models of patient-derived xenografts. In xenografts with high expression of EGFR or RET, vandetanib led to tumor regression, in those without high expression, vandeta… (full text at CIViC)

PMID 26686064 · Hatem et al., 2016 · Open in CIViC

In retrospective study, 413 patients were assessed for RSF1 amplification. 28 patients with RSF1 amplification did not show a benefit from adjuvant tamoxifen compared to placebo (12 treated vs 16 plac… (full text at CIViC)

PMID 24367492 · Keilty et al., 2013 · Open in CIViC

Of the 4854 Breast Cancer patients analyzed by Memorial Sloan Kettering-IMPACT targeted DNA sequencing and MSK-Fusion targeted RNA-seq, fusions were detected in 27 patients. One of these patients was … (full text at CIViC)

PMID 32348852 · Ross et al., 2020 · Open in CIViC

A breast cancer patient harbored the SCP2::NTRK1 fusion. This report demonstrated positive pan-tyrosine receptor kinase (TRK) immunohistochemical staining in a core-needle biopsy taken from the patien… (full text at CIViC)

PMID 33002320 · Ruiz-Cordero et al., 2020 · Open in CIViC

Mutations in SF3B1 were identified in 21/936 ER positive vs. 1/289 ER negative breast cancers. Mutation was recurrent (K700E in 74% or K666Q or K666E in another 9% of tumors). Treatment of two SF3B1 m… (full text at CIViC)

PMID 25424858 · Maguire et al., 2015 · Open in CIViC

Mutations in SF3B1 were identified in 21/936 ER positive vs. 1/289 ER negative breast cancers. Mutation was recurrent (K700E in 74% or K666Q or K666E in another 9% of tumors). Treatment of two SF3B1 m… (full text at CIViC)

PMID 25424858 · Maguire et al., 2015 · Open in CIViC

A group of 18 breast cancer patients were treated with PI3Kalpha inhibitor alpelisib (NVP-BYL719) plus an aromatase inhbitor (NCT01870505). 3 out of 3 patients expressing high tumor SGK1 mRNA had dise… (full text at CIViC)

PMID 27451907 · Castel et al., 2016 · Open in CIViC

SGK1 mRNA expression was elevated in five breast cancer cell lines which were resistant to PI3Kalpha inhibitor alpelisib (NVP-BYL719) in comparison to five sensitive cell lines. Western blots showed c… (full text at CIViC)

PMID 27451907 · Castel et al., 2016 · Open in CIViC

This study analyzed response to treatment of a heavily pre-treated biphenotypic breast carcinoma patient with a mutation in the gene STK11. The STK11 F354L alteration is associated with loss of hetero… (full text at CIViC)

PMID 28550065 · Parachoniak et al., 2017 · Open in CIViC

TROP2 T256R mutation alters the plasma membrane localization and cell-surface binding of hRS7, the humanized antibody incorporated into Sacituzumab Govitecan (SG). The TROP2 T256R encoded protein was … (full text at CIViC)

PMID 34404686 · Coates et al., 2021 · Open in CIViC

TFF3 expression was assessed by IHC in 75 patients, 187 patients were identified for the validation cohort. TFF3 expression was associated with response to endocrine therapy (tamoxifen, aminoglutethim… (full text at CIViC)

PMID 25900183 · May et al., 2015 · Open in CIViC

TIMP1 overexpression was associated with resistance to fulvestrant in breast cancer cell lines.

PMID 23881388 · Bjerre et al., 2013 · Open in CIViC

High expression of TIMP-1 was assessed by IHC in 99 primary breast cancers that had not spread beyond the breast after 6 postoperative courses of paclitaxel-based chemotherapy. High TIMP1 levels were … (full text at CIViC)

PMID 22544540 · Zhu et al., 2012 · Open in CIViC

TLK2 inhibition selectively inhibits the growth of TLK2-high breast cancer cells, downregulates ERα, BCL2 and SKP2, impairs G1/S cell cycle progression, induces apoptosis and significantly improves pr… (full text at CIViC)

PMID 27694828 · Kim et al., 2016 · Open in CIViC

Tumor mutational burden (TMB) derived from MSK-IMPACT targeted next-generation sequencing was evaluated in 7,894 breast cancers, from which 527 TMB-high tumors from 462 patients were identified. Tumor… (full text at CIViC)

PMID 40775459 · Vougiouklakis et al., 2025 · Open in CIViC

This review synthesizes current preclinical, translational, and clinical evidence evaluating tumor mutational burden (TMB) as a predictive biomarker for immune checkpoint inhibitor (ICI) response in t… (full text at CIViC)

PMID 41249701 · Das et al., 2025 · Open in CIViC

TOP1 E418K mutation and TOP1 122fs contribute to acquired resistance to Sacituzumab Govitecan (SG) therapy through alterations in the drug target TOP1. The patient, a 42-year-old female with metastati… (full text at CIViC)

PMID 34404686 · Coates et al., 2021 · Open in CIViC

In a retrospective study, TOP2A expression was assessed by IHC for 108 breast cancer patients (from TAX 303 trial). TOP2A expression was associated with a higher probability of response in doxorubicin… (full text at CIViC)

PMID 15486187 · Durbecq et al., 2004 · Open in CIViC

Cys-238 was directly bound to zinc molecule. Patients with missense mutations affecting amino acids directly involved in DNA or zinc binding displayed a very aggressive clinical phenotype. When patien… (full text at CIViC)

PMID 11051239 · Alsner et al., 2000 · Open in CIViC

In a study 202 breast cancer patients undergoing first line tamoxifen treatment, 65 patients had mutations in TP53. Among the p53 wild type population a 66% response rate was reported, where response … (full text at CIViC)

PMID 10786679 · Berns et al., 2000 · Open in CIViC

In a study of 202 breast cancer patients undergoing first line tamoxifen treatment, 65 patients had mutations in TP53. Among the p53 wild type population, a 66% response rate was reported, where respo… (full text at CIViC)

PMID 10786679 · Berns et al., 2000 · Open in CIViC

In breast cancer patients harboring TP53 mutation, mutations in conserved regions such as R249 are prognostic for a worse overall survival compared to those harboring wild-type TP53. Multivariate Cox … (full text at CIViC)

PMID 9569050 · Berns et al., 1998 · Open in CIViC

In this preclinical study, MMTV-Wnt1 mammary tumors with mutant TP53 showed a better clinical response to chemotherapy (doxorubicin) than TP53 wild-type tumors. This was mediated by wild-type TP53-ind… (full text at CIViC)

PMID 22698404 · Jackson et al., 2012 · Open in CIViC

Breast cancer patients who harbor R175H mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.

PMID 16489069 · Olivier et al., 2006 · Open in CIViC

Breast tumors in a mouse model with R172H mutation (homologous to human R175H) are more responsive to doxorubicin than breast tumors with wild type TP53.

PMID 22698404 · Jackson et al., 2012 · Open in CIViC

Breast cancer patients who harbor a R248Q mutation (N=18) have worse overall survival than those with wild type TP53 (N=1460), but have better prognosis than those with a R248W mutation (N=8).

PMID 16489069 · Olivier et al., 2006 · Open in CIViC

In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R248 (N=10, 6 at R248) are prognostic for a worse relapse-free survival compared to other non-silent mutatio… (full text at CIViC)

PMID 9569050 · Berns et al., 1998 · Open in CIViC

In breast cancer patients harboring R248W mutation, the prognosis is worse than any other hotspot TP53 mutation, as well as worse than patients with wild type TP53.

PMID 16489069 · Olivier et al., 2006 · Open in CIViC

Breast tumors with R175H or R249 mutations are more responsive to doxorubicin than breast tumors with wild type TP53.

PMID 9569050 · Berns et al., 1998 · Open in CIViC

Breast cancer patients who harbor R273C mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.

PMID 16489069 · Olivier et al., 2006 · Open in CIViC

In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R273 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53.

PMID 9569050 · Berns et al., 1998 · Open in CIViC

Breast cancer patients who harbor R273H mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.

PMID 16489069 · Olivier et al., 2006 · Open in CIViC

In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R273 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53.

PMID 9569050 · Berns et al., 1998 · Open in CIViC